EGFR and head and neck squamous cell carcinoma: Cetuximab, a monoclonal antibody that targets epidermal growth factor receptor (EGFR), is the only targeted therapy that the Food and Drug Administration currently approves to treat HNSCC as a radiation sensitizer for locoregionally advanced HNSCC (2, 3) or in combination with chemotherapy in metastatic/recurrent disease (4).